Indivior PLC (LON:INDV)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.54B |
| Revenue (ttm) | 905.57M +4.1% |
| Net Income | -47.99M |
| EPS | -0.37 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 12.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,726,430 |
| Average Volume | 704,436 |
| Open | 1,248.00 |
| Previous Close | 1,219.00 |
| Day's Range | 1,230.00 - 1,264.00 |
| 52-Week Range | 554.50 - 1,264.00 |
| Beta | 0.26 |
| RSI | 71.54 |
| Earnings Date | Jul 31, 2025 |
About Indivior
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]
Full Company ProfileNews
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder
Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergenc...
Indivior Pharmaceuticals Inc (INDV) Stock Price Up 2.7% on Mar 4
Indivior Pharmaceuticals Inc (INDV) Stock Price Up 2.7% on Mar 4
Decoding Indivior Pharmaceuticals Inc (INDV): A Strategic SWOT Insight
Decoding Indivior Pharmaceuticals Inc (INDV): A Strategic SWOT Insight
Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Indivior (INDV) Q4 2025 Earnings Call Transcript
Indivior (INDV) Q4 2025 Earnings Call Transcript
Indivior Non-GAAP EPS of $0.82 beats by $0.15, revenue of $358M beats by $52.38M
Indivior Plc. Reports Increase In Q4 Bottom Line
(RTTNews) - Indivior plc. (INDV.L) reported earnings for its fourth quarter that Increases, from last year
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, and pr...
Indivior Returns to Havas With U.S. AOR Assignment
Pharma marketer unifies creative, media, and CX under the holdco
Indivior to Participate in Upcoming Investor Conferences
RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th An...
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, ...
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq
Indivior Announces Completion of Redomiciliation to the United States
RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States.
HARBOR CAPITAL ADVISORS, INC. Buys 781 Shares of Indivior PLC (INDV)
HARBOR CAPITAL ADVISORS, INC. Buys 781 Shares of Indivior PLC (INDV)
Interesting INDV Put And Call Options For March 20th
Investors in Indivior PLC (Symbol: INDV) saw new options become available this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INDV opt...
Grail and Indivior PLC come out on top in Healthcare quant picks ahead of Q4 earnings
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus
Zacks highlights how Indivior, FIGS and Ulta Beauty delivered outsized gains as its ranks, recommendations and focus lists beat a volatile market.
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Rating | INDV Stock News
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Rating | INDV Stock News
Indivior Issues FY 2026 Financial Guidance
(RTTNews) - Indivior PLC (INDV) on Thursday has shared its financial outlook for 2026, pointing to anticipated revenue growth and improved profit margins, largely thanks to SUBLOCADE.
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Total Net Revenue Expected in the Range of $1,125 million to $1,195 million Total SUBLOCADE ® Net Revenue Expected to be in the Range of $905 million to $945 million Non-GAAP Operating Expenses Expec...
Insider Buying: Barbara Ryan Acquires Shares of Indivior PLC
Insider Buying: Barbara Ryan Acquires Shares of Indivior PLC
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table
Oregon-based Stonepine Capital Management reduced its Indivior stake by 250,000 shares in the third quarter. The overall position value fell by about $2.75 million from the previous period.
Indivior Announces Inclusion in the S&P SmallCap 600® Index
RICHMOND, Va. , Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600® index, effective today.
Indivior (INDV) Trial Shows Potential of SUBLOCADE in Reducing Opioid Use
Indivior (INDV) Trial Shows Potential of SUBLOCADE in Reducing Opioid Use